Investigating the causal effect of potential therapeutic agents for colorectal cancer prevention: a Mendelian randomization analysis
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Conventional observational studies have identified several potential therapeutic agents that may lower risk of colorectal cancer development. However, these studies are susceptible to unmeasured and residual confounding and reverse causation, undermining robust causal inference.
Methods
We used Mendelian randomization (MR), a genetic epidemiological method that can strengthen causal inference, to evaluate the effect of previously reported therapeutic agents on colorectal cancer risk, including medications, dietary micronutrients, and endogenous hormones. Genetic instruments were constructed using genome-wide association studies (GWASs) of molecular traits (e.g. circulating levels of protein drug targets, blood-based biomarkers of micronutrients). Using summary statistics from these GWASs and a colorectal cancer risk GWAS (cases=78,473, controls=107,143), we employed Wald ratios and inverse-variance weighted models to estimate causal effects.
Results
We found evidence for associations between genetically-proxied elevated omega-3 fatty acids (OR 1.10; 95% CI 1.03, 1.18; p =6.20×10 -3 ) and reduced plasma ACE levels (OR 1.08; 95% CI 1.03, 1.13; p =9.36×10 -4 ), and colorectal cancer risk. Findings for ACE inhibition were consistent across sensitivity analyses and anatomical subsites.
Conclusions
Reduced plasma ACE levels were robustly linked to increased colorectal cancer risk. Further work is required to better understand the mechanism behind this finding and whether this translates to adverse effects via medication use (i.e. ACE inhibitors).
Impact
These findings provide updated evidence on the role of previously reported therapeutic agents in colorectal cancer risk, helping to prioritise further evaluation of those agents with potential aetiological roles in cancer development.
